MAVENIR
8.9.2021 09:02:05 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Ontix, the UK based next-generation infrastructure-as-a-service provider, will be launching an Open RAN pilot for neutral host in-building connectivity in a central London office building, powered by Mavenir’s MAVair solution.
The Open RAN platform will be deployed at the Ontix Data Centre in London whilst the small cell units will be deployed at an Ontix’s customer building. The solution would enable Ontix to provide indoor mobile connectivity to typical areas like multi-tenanted offices, shopping malls, stadiums, hospitals, enterprise buildings and hot spots, delivering contiguous coverage and high-speed mobile connectivity to its enterprise customers and end consumers.
Delivering high-quality mobile connectivity indoors poses significant challenges to both operators and building owners, with a range of factors including the number of people in a building, construction materials and remote locations all impacting signal strength. It is imperative that any solution must provide service for all users, irrespective of the carrier they happen to be subscribed to, by using neutral host solutions.
Ontix and Mavenir will trial the delivery of a neutral host in-building, Open Virtualised Radio Access Network (Open vRAN) to provide enhanced connectivity. This includes the delivery and integration of Open RAN compatible, software upgradable small cells for enhanced in-building coverage and capacity.
“Open RAN is changing the dynamics of how cellular solutions are designed and delivered, and this deployment is at the cutting edge of the technology in the UK,” said Patrick Bradd, Chief Executive Officer at Ontix. “We are excited to be working on this ground-breaking Open RAN pilot to deploy a neutral host architecture to demonstrate its flexibility and how the use of commoditised hardware, can help to create the next generation of in-building networks.”
“Mavenir is delighted to partner with Ontix in addressing this demand from enterprises and consumers for mobile connectivity, especially in areas with poor indoor and in-building coverage. We are confident that using this innovative vRAN solution Ontix will be able to deliver a cost effective and a higher quality network to meet this growing demand,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
The MAVair family includes Open vRAN designed with cloud-native virtualisation techniques, enabling the RAN to flex and adapt based on usage and coverage. Mavenir’s vRAN platform provides a fully scalable virtualised network architecture with open standard interfaces, providing neutral host solution providers the option of deploying radio units from different vendors. The vRAN platform uses software running on COTS (commercial off the shelf) hardware that provides cost effectiveness, more flexibility and agility to neutral host solution providers, whilst providing one architecture for many different user scenarios.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Ontix:
Ontix is a next-generation infrastructure-as-a-service provider, disrupting the business model for delivering lightning-fast connectivity wherever it is needed. Ontix makes it cheaper, easier and quicker for mobile operators and wireless network providers to add next-generation wireless networks through its turnkey solutions. Ontix is transforming the entire process for wireless network densification by investing in shared small cell infrastructure – including connectivity – and licensing this to operators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom